

A numbered list of publications, 1.8.2025, Laura Airas

ORIGINAL ARTICLES IN INTERNATIONAL PEER-REVIEWED SCIENTIFIC JOURNALS

1. **Airas L**, Salmi M and Jalkanen S. Lymphocyte-Vascular adhesion protein-2 is a novel 70 kDa protein involved in lymphocyte adhesion to vascular endothelium. *J Immunol.* 1993; 151(8):4228-38.
2. **Airas L**, Hellman J, Salmi M, Bono P, Puurunen T, Smith DJ and Jalkanen S. CD73 is involved in lymphocyte binding to endothelium: characterization of Lymphocyte-Vascular Adhesion Protein-2 identifies it as CD73. *J Exp Med.* 1995; 182(5):1603-8.
3. **Airas L** and Jalkanen S. CD73 mediates adhesion of B cells to follicular dendritic cells. *Blood.* 1996; 88(5):1755-64.
4. **Airas L**, Niemelä J, Salmi M, Puurunen T, Smith DJ, Jalkanen S. Differential regulation and function of CD73, a glycosyl-phosphatidylinositol-linked 70-kD adhesion molecule, on lymphocytes and endothelial cells. *J Cell Biol.* 1997;136(2):421-31.
5. Arvilommi A-M, Salmi M, **Airas L**, Kalimo K and Jalkanen S. CD73 mediates lymphocyte binding to vascular endothelium in inflamed human skin. *Eur J Immunol.* 1997; 27(1):248-54.
6. **Airas L**, Niemela J and Jalkanen S. CD73-engagement promotes lymphocyte binding to endothelial cells via a lymphocyte function-associated antigen-1-dependent mechanism. *J Immunol.* 2000; 165(10):5411-17.
7. **Airas L**, Kotilainen P, Vainionpää R and Marttila RJ. Encephalitis associated with *Chlamydia pneumoniae*. *Neurology.* 2001; 56(12):1778-9.
8. Niemelä J, Henttinen T, Yegutkin G, **Airas L**, Kujari A-M, Rajala P and Jalkanen, S. Interferon-alpha induced adenosine production on the endothelium: A mechanism mediated by CD73 (Ecto-5'-Nucleotidase) upregulation. *J Immunol.* 2004; 172(3):1646-53.
9. Kotilainen P, **Airas L**, Kojo T, Kurki T, Kataja K, Minn H and Nuutila P. Positron emission tomography as an aid in the diagnosis and follow-up of Riedel's thyroiditis. *Eur J Int Med.* 2004; 15(3):186-9.
10. Kotilainen P, **Airas L**, Kojo T, Kurki T, Kataja K, Minn H, Nuutila P. Riedel's thyroiditis in a patient with multiple sclerosis. *Neuroendocrinol Lett.* 2005; 26(1):67-8.
11. Soilu-Hänninen M, **Airas L**, Mononen I, Heikkilä A, Viljanen M and Hänninen A. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. *Mult Scler.* 2005; 11(3):266-71.

12. **Airas L**, Kurki T, Erjanti H and Marttila RJ. Successful pregnancy of a patient with Balo's concentric sclerosis. *Mult Scler.* 2005; 11(3):346-8.
13. Saraste M, Kurki T and **Airas L**. Postpartum activation of multiple sclerosis: MRI imaging and immunological characterization of a case. *Eur J Neurol.* 2006; 13(1):98-9.
14. **Airas L**, Mikkola J, Vainio JM, Elovaara I and Smith DJ. Elevated serum soluble Vascular Adhesion Protein-1 (VAP-1) in patients with active relapsing remitting multiple sclerosis. *J Neuroimmunol.* 2006; 177(1-2):132-5.
15. Saraste M, Ryyänen J, Alanen A, Multanen J, Färkkilä M, Kaaja R and **Airas L**. Cerebrospinal fluid findings in multiple sclerosis patients before, during and after pregnancy. *J Neurol Neurosurg Psychiatry.* 2006; 17(10):1195-6.
16. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW; FTY 720 D2201 Study Group (**Airas L**, member of the study group). Oral fingolimod (FTY720) for relapsing multiple sclerosis. *N Engl J Med.* 2006;355(11):1124-40.
17. Saraste M, Väisänen S, Alanen A, **Airas L** and the Finnish Multiple Sclerosis and Pregnancy Study Group. Clinical and immunological evaluation of women with multiple sclerosis during and after pregnancy. *Gend Med.* 2007; 4(1):45-55.
18. Vallittu A-M, Saraste M and **Airas L**. CCR7 expression on peripheral blood lymphocytes is upregulated following treatment of multiple sclerosis with interferon-beta. *Neurol Res.* 2007; 29(8):763-6.
19. **Airas L**, Nikula T, Huang Y-H, Lahesmaa R and Wiendl H. Postpartum-activation of multiple sclerosis is associated with down-regulation of tolerogenic HLA-G. *J Neuroimmunol.* 2007; 187(1-2):205-11.
20. Saraste M, Irjala H and **Airas L**. Expansion of CD56^{Bright} natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. *Neurol Sci.* 2007; 28(3):121-6.
21. Paavilainen T, Kurki T, Parkkola R, Färkkilä M, Salonen O, Dastidar P, Elovaara I and **Airas L**. Magnetic resonance imaging of the brain used to detect early post-partum activation of multiple sclerosis. *Eur J Neurol.* 2007; 14(11):1216-21.
22. **Airas L**, Saraste M, Rinta S, Elovaara I, Huang Y-H, Wiendl H and the Finnish Multiple Sclerosis and Pregnancy Study Group. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of NK-cells. *Clin Exp Immunol.* 2008; 151(2):235-43.

23. **Airas L**, Marttila RJ and Rinne J. Methanol intoxication-induced nigrostriatal dysfunction detected using 6-[¹⁸F]fluoro-L-dopa PET. *Neurotoxicology*. 2008; 29(4):671-4
24. **Airas L**, Lindsberg PJ, Karjalainen-Lindsberg M-L, Mononen I, Kotisaari K, Smith DJ and Jalkanen S. Vascular adhesion protein-1 in human ischemic stroke. *Neuropathol Appl Neurobiol*. 2008; 34(4):394-402
25. Mills J, Thompson L, Mueller C, Waickman A, Jalkanen S, Niemela J, **Airas L** and Bynoe M. CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. *Proc Natl Acad Sci*. 2008; 105(27):9325-30
26. Niemelä J, Ifergan I, Yegutkin, G, Jalkanen S, Prat A and **Airas L**. Interferon- β regulates CD73 and adenosine expression at the blood-brain-barrier. *Eur J Immunol*. 2008; 38(10):2718-26
27. O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L; FTY720 D2201 Study Group (**Airas L**, member of the study group). Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. *Neurology*. 2009; 72(1):73-9.
28. Paavilainen T, Kurki T, Korhonen K and **Airas L**. Apparent diffusion coefficient histograms in the follow-up of relapsing-remitting multiple sclerosis. *Neuroradiol J*. 2009; 22(1):22-8.
29. zu Hörste G, Reiners J, Lehmann H, **Airas L** and Kieseier B. CD73 is expressed on invading T lymphocytes in the inflamed peripheral nerve. *Muscle and Nerve*. 2009; 40(2):287-9.
30. **Airas L**, Päivärinta M, Røyttä M, Karhu J, Kauppila M, Itälä-Remes M and Remes K. Central nervous system immune reconstitution inflammatory syndrome (IRIS) after hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2010; 45(3):593-6.
31. Rissanen E, Paavilainen T, Virta J, Marttila R, Rinne J and **Airas L**. Carbon monoxide poisoning-induced nigrostriatal dopaminergic dysfunction detected using positron emission tomography (PET). *Neurotoxicology*. 2010; 31(4):403-7.
32. **Airas L**, Jalkanen A, Alanen A, Pirttila T, and Marttila R. Breastfeeding, postpartum and pre-pregnancy disease activity in multiple sclerosis. *Neurology* 2010; 75(5):474-6.
33. Hyytiä H, Ristiniemi N, **Airas L**, Pettersson K and Hellman J. Development of an immunoassay for the detection of cystatin C dimmers. *J Immunol Methods*. 2010; 355(1-2):14-20.
34. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group (**Airas L**, member of the study group). A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *N Engl J Med*. 2010; 362(5):387-401.

35. Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L; FTY720D2201 Study Group (**Airas L**, member of the study group). Phase II study in oral fingolimod (FTY720) in multiple sclerosis: 3-year results. *Mult Scler*. 2010; 16(2):197-207.
36. Jalkanen A, Alanen A, **Airas L** and the Finnish Multiple Sclerosis and Pregnancy Study Group. Pregnancy outcome in women with multiple sclerosis - results from a prospective nationwide study in Finland. *Mult Scler*. 2010; 16(8):950-5.
37. Rinta S, **Airas L**, Elovaara I. Is the modulatory effect of pregnancy in multiple sclerosis associated with changes in blood apoptotic molecules? *Acta Neurol Scand*. 2010; 122(3):168-74.
38. Kemppainen J, Kajander S, Yli-kerttula T, **Airas L**, Seppänen M. Reversible brain hypometabolism associated with central nervous systemic lupus erythematosus (SLE). *Eur J Nucl Med Mol Imaging*. 2011;38(2):411
39. Paavilainen T, Kurki T, Färkkilä M, Salonen O, Parkkola R and **Airas L**. Lower brain diffusivity in postpartum period compared to late pregnancy: results from a prospective imaging study of multiple sclerosis patients. *Neuroradiology*. 2012; 54(8):823-8.
40. Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L; FREEDOMS study group (**Airas L**, member of the study group). Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. *Lancet Neurol*. 2012; 11(5):420-8.
41. Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L; FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group (**Airas L**, member of the study group). Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. *Arch Neurol*. 2012; 69(10):1259-69.
42. Jalkanen A, Saraste M, Gfeller A, Surcel H, **Airas L**. Increased thyroid autoimmunity among women with multiple sclerosis in the postpartum setting. *Mult Scler*. 2013; 19(13):1734-42.
43. Tenorio-Laranga J, Peltonen I, Keskitalo S, Duran-Torres G, Natarajan R, Männistö PT, Nurmi A, Vartiainen N, **Airas L**, Elovaara I, García-Horsman JA. Alteration of prolyl oligopeptidase and activated alpha-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome. *Biochem Pharmacol*. 2013; 85(12):1783-94.
44. Rissanen E, Virta J, Paavilainen T, Tuisku J, Helin S, Luoto P, Parkkola R, Rinne JO, **Airas L**. Adenosine A2A receptors in secondary progressive multiple sclerosis: a [¹¹C]TMSX brain PET study. *J Cereb Blood Flow Metab*. 2013;33(9):1394-401.

45. Dickens AM, Vainio S, Marjamäki P, Johansson J, Lehtiniemi P, Rokka J, Rinne J, Solin O, Haaparanta-Solin M, Jones P, Trigg W, Anthony DC, **Airas L**. Detection of microglial activation in an acute model of neuroinflammation using positron emission tomography and radiotracers [¹¹C]-(R)-PK11195 and [¹⁸F]GE-180. *J Nucl Med*. 2014; 55(3):466-72.
46. Rissanen E, Tuisku J, Rokka J, Paavilainen T, Parkkola R, Rinne JO and **Airas L**. *In vivo* detection of diffuse inflammation in secondary progressive multiple sclerosis using positron emission tomography imaging and radioligand [¹¹C]PK11195. *J Nucl Med*. 2014; 55(6):939-944
47. Jalkanen A, Kauko T, Koskinen JO, Waris ME and **Airas L**. Labour-associated increase in C-reactive protein concentration is not predictive of postpartum relapse activity among mothers with multiple sclerosis. *Mult Scler*. 2014; 20(13):1790-1.
48. Jalkanen A, Kauko T, Turpeinen U, Hämäläinen E and **Airas L**. Multiple sclerosis and vitamin D during pregnancy and lactation. *Acta Neurol Scand*. 2015; 131(1):64-7.
49. Rissanen E, Tuisku J, Luoto P, Arponen E, Johansson J, Oikonen V, Parkkola R, **Airas L** and Rinne JO. Automated reference region extraction and population based input function for brain [¹¹C]TMSX PET image analyses. *J Cereb Blood Flow Metab*. 2015;35(1):157-65
50. Jalkanen A, Kauko T, Koskinen JO, Waris ME, **Airas L**. Elevated concentration of C-reactive protein is associated with pregnancy-related co-morbidities but not with relapse activity in multiple sclerosis. *Neurol Sci*. 2015; 36(3):441-7.
51. **Airas L**, Dickens A, Elo P, Marjamäki P, Johansson J, Eskola O, Jones P, Trigg W, Solin O, Haaparanta-Solin M, Anthony D and Rinne J. *In vivo* PET imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis. *J Nucl Med*. 2015. 56(2):305-10.
52. **Airas L**, Säpyskä N and Broberg E. No evidence of human herpesvirus DNA in the CSF of multiple sclerosis patients. *Neurol Sci*. 2015; 36(6):1053-4.
53. Basnyat P, Hagman S, Kolasa M, Koivisto K, Verkkoniemi-Ahola A, **Airas L** and Elovaara I. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS-patients. *Mult Scler Relat Disord*. 2015; 4(4):334-8.
54. Kolasa M, Hagman S, Verkkoniemi-Ahola A, **Airas L**, Koivisto K and Elovaara I. Anti-JC virus seroprevalence in a Finnish MS cohort. *Acta Neurol Scand*. 2016; 133(5):391-7.
55. Basnyat P, Natarajan R, Vistbakka J, Lehtikangas M, **Airas L**, Matinlauri I, et al. Elevated levels of soluble CD26 and CD30 in multiple sclerosis. *Clinical and Experimental Neuroimmunology*. 2015;6(4):419-25.

56. Hovi A and **Airas L**. Effect of fingolimod-treatment on blood lipid profiles of multiple sclerosis patients. *J Neuroimmune Pharmacol*. 2016; 11(4):611-612.
57. Tarkkonen A, Rissanen E, Tuokkola T and **Airas L**. Utilization of PET imaging in differential diagnostics between a tumefactive multiple sclerosis lesion and low-grade glioma. *Mult Scler Relat Dis*. 2016; 9:147-149.
58. Saraste M, Penttilä TL and **Airas L**. Natalizumab-treatment leads to an increase in circulating CXCR3-expressing B-cells. *Neurol Neuroimmunol Neuroinflamm*. 2016; 24;3(6):e292.
59. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. (**Airas L**, member of the study group). Ocrelizumab versus placebo in primary progressive multiple sclerosis. *N Engl J Med*. 2017;376(3):209-20.
60. Sucksdorff M, Rissanen E, Tuisku J, Nuutinen S, Paavilainen T, Rokka J, Rinne J and **Airas L**. Evaluation of the effect of fingolimod treatment on microglial activation using serial PET imaging in multiple sclerosis. *J Nucl Med*. 2017; 58(10):1646-1651.
61. Schrey A, **Airas L**, Jokela M, Pulkkinen J. Botulinum toxin alleviates dysphagia of patients with inclusion body myositis. *J Neurol Sci*. 2017;380:142-7.
62. Rissanen E, Remes K, **Airas L**. Severe neutropenia after rituximab-treatment of multiple sclerosis. *Mult Scler Relat Dis*. 2017; 12(20):3-5
63. Saarela M, Senthil K, Jones J, Tienari PJ, Soilu-Hänninen M, **Airas L**, Coles A, Saarinen JT. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. *Neurology*. 2018; 90(18):849-851
64. Rissanen E, Tuisku J, Vahlberg T, Sucksdorff M, Paavilainen T, Parkkola R, Rokka J, Gerhard A, Hinz R, Talbot P, Rinne JO, **Airas L**. Microglial activation, white matter tract damage, and disability in MS. *Neurol Neuroimmunol Neuroinflamm*. 2018; 6;5(3):e443
65. Saraste M, Atula S, Hedman K, Hurme S, Jalkanen A, Sneck M, Surcel H-M, Maghzi AH and **Airas L**. Humoral response to John Cunningham Virus during pregnancy in multiple sclerosis. *Mult Scler Relat Disord*. 2018;21:11-8
66. Elo P, Tadayon S, Liljenbäck H, Teuvo J, Käkälä M, Koskensalo K, Saunavaara V, Virta J, Veres TZ, Kiviniemi A, Saraste A, Marjamäki P, **Airas L**, Jalkanen S, Roivainen A. Vascular adhesion protein-1 is actively involved in the development of inflammatory lesions in rat models of multiple sclerosis. *J Neuroinflammation*. 2018; 1;15(1):128.

67. Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators (**Airas L**, member of the study group). Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. *Lancet Neurol.* 2018; 17(5):405-415
68. Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong QM, Koedgen H, Belachew S, Tysabri Observational Program TOP (**Airas L**, member of the study group). Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. *Multiple Sclerosis and Related Disorders.* 2018;24:11-9.
69. Ponath G, Lincoln MR, Dahlawi S, Mubarak M, Sumida T, **Airas L**, Zhang S, Isitan C, Nguyen TD, Raine CS, Hafler DA, Pitt D. Enhanced astrocyte responses are driven by a genetic risk allele associated with multiple sclerosis. *Nat Commun.* 2018;9(1):5337
70. Vainio SK, Dickens AM, Tuisku J, Eskola O, Solin O, Löyttyniemi E, Anthony DC, Rinne JO, **Airas L**, Haaparanta-Solin M. Cessation of anti-VLA-4 therapy in a focal rat model of multiple sclerosis causes an increase in neuroinflammation. *EJNMMI Res.* 2019;9(1):38.
71. Kaasinen V, Joutsa J, Rissanen E, **Airas L**, Soilu-Hänninen M, Nojonen T. Progressive dopaminergic defect in a patient with primary progressive multiple sclerosis. *Mult Scler Relat Disord.* 2019;36:101385.
72. Sucksdorff M, Tuisku J, Matilainen M, Vuorimaa A, Smith S, Keitilä J, Rokka J, Parkkola R, Nylund M, Rinne J, Rissanen E, **Airas L**. Natalizumab treatment reduces microglial activation in the white matter of the MS brain. *Neurol Neuroimmunol Neuroinflamm.* 2019;6(4):e574.
73. Tuisku J, Plavén-Sigray P, Gaiser EC, **Airas L**, Al-Abdulrasul H, Brück A, Carson RE, Chen MK, Cosgrove KP, Ekblad L, Esterlis I, Farde L, Forsberg A, Halldin C, Helin S, Kosek E, Lekander M, Lindgren N, Marjamäki P, Rissanen E, Sucksdorff M, Varrone A; HRRT [11C]PBR28 study group, Collste K, Gallezot JD, Hillmer A, Huang Y, Höglund CO, Johansson J, Jucaite A, Lampa J, Nabulsi N, Pittman B, Sandiego CM, Stenkrona P, Rinne J, Matuskey D, Cervenka S. Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [¹¹C]PBR28 HRRT PET study. *Eur J Nucl Med Mol Imaging.* 2019;46(11):2329-38.
74. Elo P, Li XG, Liljenbäck H, Helin S, Teuho J, Koskensalo K, Saunavaara V, Marjamäki P, Oikonen V, Virta J, Chen Q, Low PS, Knuuti J, Jalkanen S, **Airas L**, Roivainen A. Folate receptor-targeted positron emission tomography of experimental autoimmune encephalomyelitis in rats. *J Neuroinflammation.* 2019;16(1):252.
75. Högel H, Rissanen E, Barro C, Matilainen M, Nylund M, Kuhle J, **Airas L**. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. *Multiple Sclerosis Journal.* 2020;26(2):210-9.

76. **Airas L**, Nylund M, Mannonen I, Matilainen M, Sucksdorff M, Rissanen E. Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland. *Mult Scler Relat Disord.* 2020;40:101980.
77. Kortela E, Kanerva MJ, Puustinen J, Hurme S, **Airas L**, Lauhio A, Hohenthal U, Jalava-Karvinen P, Nieminen T, Finnilä T, Häggblom T, Pietikäinen A, Koivisto M, Vilhonen J, Marttila-Vaara M, Hytönen J, Oksi J. Oral doxycycline compared to intravenous ceftriaxone in the treatment of Lyme neuroborreliosis: a multicentre, equivalence, randomized, open-label trial. *Clin Infect Dis.* 2020: ciaa217
78. Bezukladova S, Tuisku J, Matilainen M, Vuorimaa A, Nylund M, Smith S, Sucksdorff M, Mohammadian M, Saunavaara V, Laaksonen S, Rokka J, Rinne J, Rissanen E, **Airas L**. Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging. *Neurol Neuroimmunol Neuroinflamm.* 2020;7(3).
79. Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I, Kasliwal R, Jaitly S, Campbell N, Ho PR, Licata S; Tysabri Observational Program (TOP) Investigators (**Airas L**, member of the study group). Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). *Journal of Neurology, Neurosurgery & Psychiatry.* 2020;91(6):660.
80. Sucksdorff M, Matilainen M, Tuisku J, Polvinen E, Vuorimaa A, Rokka J, Nylund M, Rissanen E, **Airas L**. Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis. *Brain.* 2020;5;143(11):3318-3330
81. Smith E, Jaakonmäki N, Nylund M, Kupila L, Matilainen M, **Airas L**. Frequency and etiology of acute transverse myelitis in Southern Finland. *Mult Scler Relat Disord.* 2020;46:102562.
82. Nylund M, Vuorinen T, **Airas L**. Drug reaction with eosinophilia and systemic symptoms after ocrelizumab therapy. *Multiple Sclerosis and Related Disorders.* 2020;42:102058.
83. Saraste M, Bezukladova S, Matilainen M, Tuisku J, Rissanen E, Sucksdorff M, Laaksonen S, Vuorimaa A, Kuhle J, Leppert D, **Airas L**. High serum neurofilament associates with diffuse white matter damage in MS. *Neurol Neuroimmunol Neuroinflamm.* 2020;8(1):e926.
84. Saraste M, Bezukladova S, Sucksdorff M, Saunavaara V, Rissanen E, Matilainen M, **Airas L**. Fingolimod treatment reverses signs of diffuse white matter damage in multiple sclerosis: A pilot study. *Mult Scler Relat Disord.* 2021;48:102690.
85. Elo P, Li XG, Liljenbäck H, Gardberg M, Moisio O, Miner M, Virta J, Saraste A, Srinivasarao M, Pugh M, Low PS, Knuuti J, Jalkanen S, **Airas L**, Lu YJ, Roivainen A. Efficacy and tolerability of folate-aminopterin therapy in a rat focal model of multiple sclerosis. *J Neuroinflammation.* 2021;18:30

86. Søndergaard HB, **Airas L**, Christensen JR, Nielsen BR, Börnsen L, Oturai A, Sellebjerg F. Pregnancy-induced changes in microRNA expression in multiple sclerosis. *Front. Immunol.* 2021;11(3465).
87. Saraste M, Bezukladova S, Matilainen M, Sucksdorff M, Kuhle J, Leppert D and **Airas L**. Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis: GFAP and DTI. *Mult Scler Relat Disord.* 2021;50:102810.
88. Jambor I, Steiner A, Pesola M, Liimatainen T, Sucksdorff M, Rissanen E, **Airas L**, Aronen HJ, Merisaari H. Whole Brain Adiabatic $T_{1\rho}$ and Relaxation Along a Fictitious Field Imaging in Healthy Volunteers and Patients With Multiple Sclerosis: Initial Findings. *J Magn Reson Imaging.* 2021;54(3):866-879.
89. Waggan I, Rissanen E, Tuisku J, Matilainen M, Helin S, Parkkola R, Rinne JO, **Airas L**. Effect of dopaminergic medication on adenosine 2A receptor availability in patients with parkinson's disease. *Parkinsonism Relat Disord.* 2021;86:40-44.
90. Nylund M, Sucksdorff M, Matilainen M, Polvinen E, Tuisku J, **Airas L**. Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET. *Brain Commun.* 2021;4(1):fcab301. eCollection 2022 Feb.
91. Vainio SK, Dickens AM, Matilainen M, López-Picón FR, Aarnio R, Eskola O, Solin O, Anthony DC, Rinne OJ, **Airas L**, Haaparanta-Solin M. Dimethyl fumarate decreases short-term but not long-term inflammation in a focal EAE model of neuroinflammation. *EJNMMI Res.* 2022;12(6).
92. Saraste M, Matilainen M, Rajda C, Galla Z, Sucksdorff M, Vécsei L, **Airas L**. Association between microglial activation and serum kynurenine pathway metabolites in multiple sclerosis patients. *Mult Scler Relat Disord.* 2022;59:103667.
93. Misin O, Matilainen M, Nylund M, Honkonen E, Rissanen E, Sucksdorff M, **Airas L**. Innate Immune Cell-Related Pathology in the Thalamus Signals a Risk for Disability Progression in Multiple Sclerosis. *Neurol Neuroimmunol Neuroinflamm.* 2022;9(4):e1182.
94. Huang Y, Giacomini PS, Venkateswaran S, Trudelle A-M, Fadda G, Sharifian-Dorche M, Boudjani H, Poliquin-Lasnier L, **Airas L**, Saveriano A, Ziller MG, Miller E, Martinez-Rios Arellano C, Wilson N, Davila J, Rush C, Longbrake EE, Longoni G, Macaron G, Bernard G, Tampieri D, Antel J, Brais B, La Piana R, White Matter Rounds Network. The White Matter Rounds Experience: The Importance of a Multidisciplinary International Network to Accelerate the Diagnostic Process for Adult Patients with Rare White Matter Disorders. *Front Neurol.* 2022;13:928493.
95. Waggan I, Rissanen E, Tuisku J, Joutsa J, Helin S, Parkkola R, Rinne JO, **Airas L**. Adenosine A2A receptor availability in patients with early and moderate stage Parkinson's disease. *J Neurol.* 2023;270(1):300-310

96. Lotila J, Hyvärinen T, Skottman H, **Airas L**, Narkilahti S, Hagman S. Establishment of a human induced pluripotent stem cell line (TAUi008-A) derived from a multiple sclerosis patient. *Stem Cell Res.* 2022;63:102865.
97. Lehto J, Sucksdorff M, Nylund M, Raitanen R, Matilainen M, **Airas L**. PET-measurable innate immune cell activation reduction in chronic active lesions in PPMS brain after rituximab treatment: a case report. *J Neurol.* 2023;270(4):2329-2332.
98. Saraste M, Matilainen M, Vuorimaa A, Laaksonen S, Sucksdorff M, Leppert D, Kuhle J, **Airas L**. Association of serum neurofilament light with microglial activation in multiple sclerosis. *J Neurol Neurosurg Psychiatry.* 2023;94(9):698-706.
99. Lehto J, Nylund M, Matilainen M, Sucksdorff M, Vuorimaa A, Rajander J, Wahlroos S, Hariri P, **Airas L**. Longitudinal stability of progression-related microglial activity during teriflunomide treatment in patients with multiple sclerosis. *Eur J Neurol.* 2023;270(4):2329-2332
100. Laaksonen S, Saraste M, Sucksdorff M, Nylund M, Vuorimaa A, Matilainen M, Heikkinen J, **Airas L**. Early prognosticators of later TSPO-PET-measurable microglial activation in multiple sclerosis. *Mult Scler Relat Dis.* 2023;75:104755.
101. Polvinen E, Matilainen M, Nylund M, Sucksdorff M, **Airas L**. TSPO-detectable chronic active lesions predict disease progression in multiple sclerosis. *Neurol Neuroimmunol Neuroinflamm.* 2023;10(5):e200133.
102. Waggan I, Rissanen E, Tuisku J, Matilainen M, Parkkola R, Rinne JO, **Airas L**. Adenosine A2A receptor availability in cerebral gray and white matter of patients with Parkinson's disease. *Parkinsonism Relat Disord.* 2023;113:105766
103. Laaksonen S, Saraste M, Nylund M, Hinz R, Snellman A, Rinne J, Matilainen M, Airas L. Sex-driven variability in TSPO-expressing microglia in MS patients and healthy individuals. *Front Neurol.* 2024 Feb 20;15:1352116.
104. Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators (**Airas L** part of the investigators). Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. *Lancet Neurol.* 2024 Nov;23(11):1119-1132.
105. Scalfari A, Traboulsee A, Oh J, **Airas L**, Bittner S, Calabrese M, Garcia Dominguez JM, Granziera C, Greenberg B, Hellwig K, Illes Z, Lycke J, Popescu V, Bagnato F, Giovannoni G. Smouldering-Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions. *Ann Neurol.* 2024 Nov;96(5):826-845.
106. Lehto J, Aarnio R, Tuisku J, Sucksdorff M, Koivumäki EM, Nylund M, Helin S, Rajander J, Danon J, Gilchrist J, Kassiou M, Oikonen V, **Airas L**. P2X 7-receptor binding in new-onset and secondary progressive MS - a [11C]SMW139 PET study. *EJNMMI Res.* 2024 Dec 5;14(1):123.

107. Radford-Smith DE, Yates AG, Kacerova T, Nylund M, Sucksdorff M, Matilainen M, Willemse E, Oechtering J, Maleska Maceski A, Leppert D, Kuhle J, Probert F, Anthony DC, **Airas L**. Integrating TSPO-PET imaging with metabolomics for enhanced prognostic accuracy in multiple sclerosis. *BMJ Neurol Open*. 2025;7(1):e001026
108. Klotz L, Smolders J, Lehto L, Matilainen M, Lütje L, Buchholz L, Albrecht S, Walter C, Varghese J, Wiendl H, Nylund M, Thomas C, Gardberg M, van den Bosch AMR, **Airas L**, Huitinga I, Kuhlmann T. Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis. *Nat Med*. 2025 Jun;31(6):2016-2026
109. Zeydan B, Neyal N, Son J, Schwarz CG, Kendall Thomas JC, Morrison HA, Bush ML, Reid RI, Przybelski SA, Fought AJ, Jack CR, Petersen RC, Kantarci K, Lowe VJ, **Airas L**, Kantarci OH. Microglia positron emission tomography and progression in multiple sclerosis: thalamus on fire. *Brain Commun*. 2025 Apr 16;7(3):fcf141
110. Ahola V, Saraste M, Nylund M, Matilainen M, Luoma A, Vuorimaa A, Lehto J, Laaksonen S, Brockmann EC, Kuhle J, Leppert D, Soukka T, Lamminmäki U, **Airas L**. Plasma CHI3L1 associates with brain volume loss and glial activation in multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2025 May 16;jnnp-2025-336063.
111. Alfaifi BQ, Tuisku J, Matilainen M, Anton-Rodriguez J, Lewis D, Jackson A, Coope DJ, **Airas L**, Deakin B, Herholz K, Gerhard A, Hinz R. Hemispheric asymmetry of [11C](R)PK11195 binding to translocator protein 18 kDa (TSPO) in normal brain. *J Cereb Blood Flow Metab*. 2025 Jun 19:271678X251348790
112. Luoma A, Matilainen M, Tuisku JM, Aarnio R, Nikkilä T, Laaksonen S, Koivumäki M, Honkonen E, Nylund M, Wahlroos S, Solin O, Chen MK, Toyonaga T, Lehto J, Snellman A, Rinne JO, **Airas L**. Synaptic Density in Multiple Sclerosis: An In Vivo Study Using [11C]UCB-J-PET Imaging. *Neurol Neuroimmunol Neuroinflamm*. 2025 Sep;12(5):e200435

REVIEWS IN INTERNATIONAL PEER-REVIEWED SCIENTIFIC JOURNALS

113. **Airas L**. CD73 and Adhesion of B cells to follicular dendritic cells. *Leukemia and Lymphoma*. 1998; 29(1-2):37-47.
114. Huang Y-H, **Airas L**, Schwab N and Wiendl H. Janus head: the dual role of HLA-G in CNS immunity. *Cell Mol Life Sci*. 2011; 68(3):407-16.
115. de Sa JC, **Airas L**, Bartholome E, Grigoriadis N, Mattle H, Oreja-Guevara C, O'Riordan J, Sellebjerg F, Stankoff B, Vass K, Walczak A, Wiendl H, Kieseier BC. Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. *Ther Adv Neurol Disord*. 2011; 4(3):139-68.
116. **Airas L** and Kaaja R. Pregnancy and multiple sclerosis. *Obstet Med*. 2012;5(3):94-7.
117. Oreja-Guevara C, Wiendl H, Kieseier BC and **Airas L** for the NeuroNet Study Group. Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner. *Ther Adv Neurol Disord*. 2014;7(2):137-49.

118. De Stefano N, **Airas L**, Grigoriadis N, Mattle HP, O'Riordan J, Oreja-Guevara C, Sellebjerg F, Stankoff B, Walczak A, Wiendl H, Kieseier BC. Clinical relevance of brain volume measures in multiple sclerosis. *CNS drugs*. 2014; 28(2):147-56.
119. **Airas L**. Hormonal and gender related immune changes in multiple sclerosis. *Acta Neurol Scand*. 2015; 132(199):62-70.
120. **Airas L**, Rissanen E and Rinne J. Imaging neuroinflammation in multiple sclerosis using TSPO PET. *Clin Transl Imaging*. 2015; 3(6):461-73.
121. Gilmore W and **Airas L**. Successive pregnancies in multiple sclerosis. *Neurology*. 2016; 87(13):1316-7.
122. **Airas L**, Rissanen E, Rinne J. Imaging of microglial activation in MS using PET: Research use and potential future clinical application. *Mult Scler*. 2017;23(4):496-504.
123. Vuorimaa A, Rissanen E, **Airas L**. In vivo PET imaging of adenosine 2A receptors in neuroinflammatory and neurodegenerative disease. *Contrast Media & Molecular Imaging*. 2017;2017:15.
124. **Airas L**, Nylund M, Rissanen E, Evaluation of microglial activation in multiple sclerosis patients using positron emission tomography. *Front Neurol*. 2018 26;9:181.
125. Högel H, Rissanen E, Vuorimaa A, **Airas L**. Positron emission tomography imaging in evaluation of MS pathology in vivo. *Mult Scler*. 2018;24(11):1399-412.
126. Waubant E, Amezcua L, Sicotte N, Hellwig K, Krupp L, Weinstock-Guttman B, Yeh A, Lucas RM, Longbrake EE, Yadav V, Rensel M, Mar S, Hersh C, Block V, Zipp F, Han MH, Spain R, Kelland EE, Charvet L, Dimitri D, Papeix C, Cross AH, Inglese M, Amato MP, **Airas L**. et al. Gender Inequities in the Multiple Sclerosis Community: A Call for Action. *Annals of Neurology*. 2018;84(6):958-9.
127. Bodini B, Tonietto M, **Airas L**, Stankoff B. Positron Emission Tomography in Multiple Sclerosis: Straight to the Target. *Nat Rev Neurol*. 2021;17(11):663-675.
128. Reyes S, Cunningham AL, Kalincik T, Kubala Havrdova E, Isobe N, Pakpoor J, **Airas L**, Bunyan RF, van der Walt A, Oh J, Mathews J, Mateen FJ, Giovannoni G. Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. *J Neuroimmunol*. 2021;357:577627.
129. Möck AE, Honkonen E, **Airas L**. Synaptic Loss in Multiple Sclerosis: A Systematic Review of Human Post-Mortem Studies. *Front Neurol*. 2021;12:782599.
130. Giovannoni G, Popescu V, Wuerfel J, Hellwig K, Iacobus E, Jensen M B, Garcia-Dominguez J M, Sousa L, De Rossi N, Hupperts R, Fenu G, Bodini B, Kuusisto HM, Stankoff B, Lycke J, **Airas L**, Granziera C, Scalfari A. Smouldering multiple sclerosis: the 'real MS'. *Ther Adv Neurol Diso*. 2022;15:17562864211066751.

131. **Airas L**, & Yong V. W. Microglia in multiple sclerosis - pathogenesis and imaging. *Curr Opin Neurol*. 2022;35(3), 299–306.
132. Pitt D, Lo CH, Gauthier SA, Hickman RA, Longbrake E, **Airas L**, Mao-Draayer Y, Riley C, De Jager PL, Wesley S, Boster A, Topalli I, Bagnato F, Mansoor M, Stuve O, Kister I, Pelletier D, Stathopoulos P, Dutta R, Lincoln MR. Toward Precision Phenotyping of Multiple Sclerosis. *Neurol Neuroimmunol Neuroinflamm*. 2022;9(6):e200025.
133. Van Wijmeersch B, Hartung HP, Vermersch P, Pugliatti M, Pozzilli C, Grigoriadis N, Alkhawajah M, **Airas L**, Linker R, Oreja-Guevara C. Using Personalized Prognosis in the Treatment of Relapsing Multiple Sclerosis: A Practical Guide. *Front Immunol*. 2022;13: :991291
134. Pugliatti M, Hartung HP, Oreja-Guevara C, Pozzilli Carlo, **Airas L**, Alkhawajah M, Grigoriadis N, Magyari M, Van Wijmeersch B, Zakaria M, Linker R, Chan A, Vermersch P, Berger T. Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in. *Front Immunol*. 2022;13:1045101.
135. Pozzilli C, Pugliatti M, Vermersch P, Grigoriadis N, Alkhawajah M, **Airas L**, Oreja-Guevara C. Diagnosis and treatment of progressive multiple sclerosis: A position paper. *Eur J Neurol*. 2023;30(1):9-21.
136. Oh J, **Airas L**, Harrison D, Järvinen E, Livingston T, Lanker S, Malik RA, Okuda DT, Villoslada P, de Vries HE. Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation. *Front Neurol*. 2023;14:1319869.
137. **Airas L**, Bermel RA, Chitnis T, Hartung HP, Nakahara J, Stuve O, Williams MJ, Kieseier BC, Wiendl H. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis. *Ther Adv Neurol Disord*. 2024;17:17562864241233041.
138. Berger T, Zeitlinger M, Popescu V, Magyari M, **Airas L**, Alkhawajah M, Pugliatti M, Zakaria M, Pozzilli C, Drulovic J, Van Wijmeersch B, Vermersch P, Oreja-Guevara C. Generics, Biosimilars and Follow-On Non-Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European Neurologists. *Eur J Neurol*. 2025;32(4):e70140
139. Vermersch P, **Airas L**, Berger T, Deisenhammer F, Grigoriadis N, Hartung HP, Magyari M, Popescu V, Pozzilli C, Pugliatti M, Van Wijmeersch B, Zakaria M, Oreja-Guevara C. The role of microglia in multiple sclerosis: implications for treatment with Bruton's tyrosine kinase inhibitors. *Front Immunol*. 2025 May 15;16:1495529
140. Klotz L, Saraste M, **Airas L**, Kuhlmann T. Multiple sclerosis: 2024 update. *Free Neuropathol*. 2025 Jul 8;6:14

ORIGINAL ARTICLES IN DOMESTIC PEER-REVIEWED JOURNALS

141. **Airas L**, Nylund M, Mannonen I, Sucksdorff M, Rissanen E. Rituksimabi MS-taudin hoidossa. *Duodecim*, 2019;135(10):943-52
142. Jokela M, Martikainen M, Lund-Aho T, Palmio J, **Airas L**, Hietaharju A, Kaasinen V. CANVAS - tasapainovaikeuksien ja kroonisen yskän mahdollinen aiheuttaja. 2022;138(2):187-190.

REVIEWS IN DOMESTIC PEER-REVIEWED JOURNALS

143. **Airas L**, Alanen A and Lehtonen L. Treatment of relapsing multiple sclerosis during pregnancy. *Duodecim*. 2004; 120:428-9.
144. **Airas L**, Korja M, Soinio M, Nuutila P, Knip M ja Marttila R. Stiff-person syndrome. *Duodecim*. 2004; 120:1899-902.
145. **Airas L**. Demyelinating lesions as an incidental finding in magnetic resonance imaging of the brain – what shall I tell the patient. *Duodecim*. 2009; 125:1201-7.
146. **Airas L**. How to examine a patient with paresthesia. *Suom Lääkäril*. 2010;33: 2577-82.
147. Ruuskanen J, Malm H, **Airas L**. Multiple sclerosis and pregnancy. *Duodecim*. 2013; 129(14):1457-64.
148. **Airas L**, Rissanen E, Sucksdorff M, Paavilainen T, Kurki T, Rinne J. Imaging of multiple sclerosis. *Kuvantaminen MS-taudissa*. *Suom Lääkäril*. 2015.
149. **Airas L**, Atula S, Kuusisto H, Nylund M, Soilu-Hänninen M, Verkkoniemi-Ahola A, Tienari P. Monoklonaaliset vasta-aineet MS-taudin hoidossa. *Duodecim*. 2018; 134(6):565–72
150. Saraste M and **Airas L**. Mikroglia-solut – aivojen puhdistajat ja puolustajat. *Duodecim*. 2020;136(7):751-8
151. **Airas L**, Saraste M, Parkkali T, Päivärinta M, Kupila L. Akuutti transversaalimyeliitti vaatii nopean hoidon. *Duodecim*. 2021;137(18):1941-9
152. Soilu-Hänninen M, Anttonen J, **Airas L**, Hietaharju A. Neurosarkoidoosin uudistunut diagnostiikka ja tehostunut hoito. *Duodecim*. 2021;137(18):1915-23
153. Saraste M and **Airas L**. Raskauden vaikutukset soluvälitteisiin autoimmuunitauteihin - erityisesti MS-tautiin. *Duodecim*. 2022;138(8):677-84
154. Laakso S, Hietaharju A and **Airas L**. Neuroimmunologian kehittyvät hoidot. *Duodecim*. 2025;141(1):75-83

INTERNATIONAL TEXTBOOKS AND CHAPTERS IN TEXTBOOKS

155. **Airas L**, Etemadifar M, Maghzi A-H. Neurological disorders and pregnancy. 2011. Elsevier Inc. Chapter 1. Pregnancy and Multiple Sclerosis.

156. Hellwig K, Zurawski B, **Airas L** and Smith EK. Health Issues in Women with Multiple Sclerosis. 2017. Springer-Verlag Wien. Chapter Fertility and Assisted Reproductive Techniques in Women with MS.

DOMESTIC TEXTBOOKS AND CHAPTERS IN TEXTBOOKS

157. **Airas L**. Finnish textbook of neuroimmunology. 2006. Editors Elovaara, Pirttilä, Färkkilä ja Hietaharju. Chapter Pregnancy, breastfeeding and immune-mediated diseases. 267-75.
158. **Airas L** and Karvonen M. Finnish textbook of pharmacology and toxicology. 8th edition. 2012. Editors Koulu M, Mervaala E and Tuomisto J. Chapter Treatment of multiple sclerosis. 857.
159. **Airas L** and Färkkilä M. Finnish textbook of hand surgery. 2nd edition. 2012. Chapter Neurological problems associated with upper extremities.
160. Hämäläinen P, Smith E, **Airas L**. Finnish textbook of clinical neuropsychiatry. 2nd edition. 2021. Editors Juva K, Hublin C, Kalska H, Korkeila J, Sainio M, Tani P, Vataja R. Chapter 19 MS-disease.

OTHER PUBLICATIONS

161. **Airas L**. (1996). On the role of CD73 in lymphocyte adhesion. ANNALES-UNIVERSITATIS TURKUENSIS SERIES D, 1996, Turku, Turun yliopisto.
162. **Airas L**, Niemelä J, Yegutkin G, Jalkanen S. Mechanism of action of IFN-beta in the treatment of multiple sclerosis: a special reference to CD73 and adenosine. Ann N Y Acad Sci. 2007; 1110:641-8.
163. Remes A, **Airas L**, Atula S, Färkkilä M, Hartikainen P, Koivisto K, Mäenpää E, Ruutiainen J, Sumelahti ML. Update on current care guideline: Multiple sclerosis. Duodecim. 2015; 131(5):500-1.
164. **Airas L**. Exposure to natalizumab during pregnancy and lactation is safe - No. Multiple Sclerosis Journal. 2020;26(8):889-91.
165. Laaksonen S, Sucksdorff M, **Airas L**. MS-taudin varhainen ja tehokas hoito kannattaa. Erikaislääkärilehti. 2022;1:23-27.
166. Tienari P, **Airas L**. Epstein-Barrin virus MS-taudin ajurina. Duodecim. 2022;138(9):743-5
167. Kortela E, Kanerva M, Kurkela S, Hytönen J, Jarva H, Pietikäinen A, **Airas L**, Nieminen T, Peltola V, Oksi J, Järvinen A, Pitkäpaasi M, Nyman D, Tikkala J, Linden M, Perander L, Nordberg M. Lymen borreliosii : suositus diagnostiikasta ja hoidosta. Lääkärilehti. 2023;78: e37538
168. Airas L. Bruton's tyrosine kinase inhibitors for multiple sclerosis. Lancet Neurol. 2025 Aug;24(8):627-628